Combination therapies with PI3K inhibition have been shown to enhance the effect of MEK inhibition within basal subtype breast cancer cells by alleviating the compensatory activation of PI3K/AKT that occurs with MEK inhibition [109]. Here, MAP2K7 is linked to breast carcinoma.